These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 23270985

  • 1. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Novitzky N, Thomas V, du Toit C.
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):584-8. PubMed ID: 23270985
    [Abstract] [Full Text] [Related]

  • 2. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Novitzky N, Thomas V, du Toit C, McDonald A.
    Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
    [Abstract] [Full Text] [Related]

  • 3. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [Abstract] [Full Text] [Related]

  • 4. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Rzepecki P, Sarosiek T, Szczylik C.
    Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
    [Abstract] [Full Text] [Related]

  • 5. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B.
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [Abstract] [Full Text] [Related]

  • 6. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, Kondo Y, Nakao S, Nagafuji K, Miyamoto T, Kurokawa M, Okoshi Y, Chiba S, Ohashi Y, Takaue Y, Taniguchi S.
    Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
    [Abstract] [Full Text] [Related]

  • 7. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, Kim SY, Lee YH, Lim YT, Yoo KH, Sung KW, Koo HH, Im HJ, Seo JJ, Park SK, Ahn HS, Korean Society of Pediatric Hematology-Oncology.
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [Abstract] [Full Text] [Related]

  • 8. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Sobrevilla-Calvo P, Rivas-Vera S, Gómez-Rangel JD, Ruiz-Argüelles GJ.
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [Abstract] [Full Text] [Related]

  • 9. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia--a single-center experience.
    Wang H, Wang Z, Zheng X, Ding L, Zhu L, Yan H, Guo Z.
    Cytotherapy; 2013 Sep; 15(9):1118-25. PubMed ID: 23806238
    [Abstract] [Full Text] [Related]

  • 10. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
    [Abstract] [Full Text] [Related]

  • 11. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K, Patel M, Rasheed W, Saleh AJ, Bakr M, Ahmed S, Ibrahim K, Hussain F, Elkum N, Elhassan T, Nurgat Z, Chaudhri N, Aljurf M.
    Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
    [Abstract] [Full Text] [Related]

  • 12. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen.
    Wang SB, Li L, Pan XH, Hu DM, Peng LH, Liu L, Xie ZJ, Yin B, Sun XJ, Yu J, Liang Y.
    Clin Transplant; 2013 May; 27(2):E109-15. PubMed ID: 23387380
    [Abstract] [Full Text] [Related]

  • 13. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R, Prem S, Mahapatra M, Seth T, Chowdhary DR, Mishra P, Pillai L, Narendra AM, Mehra NK, Saxena R, Choudhry VP.
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
    Okuda S, Terasako K, Oshima K, Sato M, Nakasone H, Kako S, Yamazaki R, Tanaka Y, Tanihara A, Higuchi T, Nishida J, Kanda Y.
    Am J Hematol; 2009 Mar; 84(3):167-9. PubMed ID: 19195036
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
    Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, Shah AJ, Kapoor N.
    Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
    [Abstract] [Full Text] [Related]

  • 17. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Kim H, Lee JH, Joo YD, Bae SH, Hyun MS, Lee JH, Kim DY, Lee WS, Ryoo HM, Kim MK, Park JH, Lee KH, Cooperative Study Group A for Hematology (COSAH).
    Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia].
    Sun C, Lin X, Huang Y, Song C, Tao Y, Tu S, Fang J, Chen T, Sun C, Wu B.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):221-4. PubMed ID: 24666488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.